

**FINANCIAL STATEMENTS 2009
OF THE PARENT COMPANY
NNE Pharmaplan A/S**

Annual report for the Parent Company NNE Pharmaplan A/S
is an integrated part of the Annual Report 2009 for NNE Pharmaplan

Financial statements of the Parent company NNE Pharmaplan A/S

(DKK 1,000)

		<u>2009</u>	<u>2008</u>
	Note		
Sales	2	979,671	1,198,338
Cost of sales	3	<u>(811,717)</u>	<u>(1,051,126)</u>
Gross profit		<u>167,954</u>	<u>147,212</u>
Sales and distribution costs	3	(32,039)	(25,164)
Administrative expenses	3	<u>(84,902)</u>	<u>(94,119)</u>
Operating profit		<u>51,013</u>	<u>27,929</u>
Share of profit/loss in subsidiaries		(18,866)	(71,321)
Financial income	4	2,746	3,235
Financial expenses	5	<u>(11,019)</u>	<u>(7,650)</u>
Profit before income taxes		<u>23,874</u>	<u>(47,807)</u>
Income taxes		<u>(12,995)</u>	<u>(9,940)</u>
Net profit		<u>10,879</u>	<u>(57,747)</u>
Proposed appropriation of net profit:			
Dividend to shareholders		-	-
Retained earnings		10,879	(57,747)
Reserve for net revaluation under the equity method		<u>-</u>	<u>-</u>
		<u>10,879</u>	<u>(57,747)</u>

Financial statements of the Parent company NNE Pharmaplan A/S

Balance Sheet

(DKK 1,000)

ASSETS		<u>31 Dec 2009</u>	<u>31 Dec 2008</u>
	Note		
Intangible assets	6	1,700	3,045
Property, plant and equipment	7	9,739	16,687
Investments in subsidiaries	8	133,855	20,929
Deferred income tax assets		<u>8,726</u>	<u>10,040</u>
Total non-current assets		<u>154,020</u>	<u>50,701</u>
Work in progress and payments on accounts	9	2,535	48,212
Trade receivables		48,127	95,228
Receivables from related parties		190,389	219,577
Tax receivables		6,716	2,705
Other receivables and prepayments		2,938	36,382
Prepayments		5,785	14,589
Cash at bank and in hand		<u>55,577</u>	<u>1,065</u>
Total current assets		<u>312,067</u>	<u>417,758</u>
TOTAL ASSETS		<u>466,087</u>	<u>468,459</u>

Financial statements of the Parent company NNE Pharmaplan A/S

Balance Sheet

(DKK 1,000)

EQUITY AND LIABILITIES		<u>31 Dec 2009</u>	<u>31 Dec 2008</u>
	Note		
Share capital	10	500	500
Retained earnings		<u>119,074</u>	<u>103,915</u>
Total equity		<u>119,574</u>	<u>104,415</u>
Loans and payables to related parties	14	37,613	58,124
Provisions		<u>28,142</u>	<u>18,458</u>
Total non-current liabilities		<u>65,755</u>	<u>76,582</u>
Payments on account for work in progress	9	3,966	7,536
Trade payables		40,786	59,368
Payables to related parties	14	60,598	37,339
Short term borrowing related parties	14	18,807	33,007
Provisions		1,171	2,969
Other liabilities	11	<u>155,430</u>	<u>147,243</u>
Total current liabilities		<u>280,758</u>	<u>287,462</u>
Total liabilities		<u>346,513</u>	<u>364,044</u>
TOTAL EQUITY AND LIABILITIES		<u>466,087</u>	<u>468,459</u>

Parent Company - Statement of changes in Equity

(DKK 1,000)

	Share Capital	Reserve under the equity method	Retained earnings	Dividend	Total
2009					
Balance at beginning of year	500	-	103,915	-	104,415
Exchange rate adjustments of investment in subsidiaries	-	-	(627)	-	(627)
Adjustment of investment in subsidiary prior year	-	-	11,045	-	11,045
Realised loss on options used paid to parent company	-	-	(6,658)	-	(6,658)
Net income/(loss) recognised directly in equity	-	-	3,760	-	3,760
Net profit/(loss)	-	-	10,879	-	10,879
Total income/(loss)	-	-	14,639	-	14,639
Cost of share-based payment	-	-	520	-	520
Proposed dividend 2009	-	-	-	-	-
Balance end of year	500	-	119,074	-	119,574

Share Capital and Reserve under equity method can not be used for dividend declaration.

	Share Capital	Reserve under the equity method	Retained earnings	Dividend	Total
2008					
Balance beginning of year	500	-	181,539	-	182,039
Exchange rate adjustments of investment in subsidiaries	-	-	(2,437)	-	(2,437)
Adjustment of investment in subsidiary prior year	-	-	(13,848)	-	(13,848)
Realised loss on options used paid to parent company	-	-	(6,709)	-	(6,709)
Net income/(loss) recognised directly in equity	-	-	(22,994)	-	(22,994)
Net profit/(loss)	-	-	(57,747)	-	(57,747)
Total income/(loss)	-	-	(80,741)	-	(80,741)
Cost of share-based payment	-	-	3,117	-	3,117
Proposed dividend 2008	-	-	-	-	-
Balance end of year	500	-	103,915	-	104,415

Share Capital and Reserve under equity method can not be used for dividend declaration.

Notes – Parent Company

Note 1 Accounting Policies of the Parent Company

The Parent Company's Financial Statements have been prepared in accordance with the Danish Financial Statements Act class C/large companies.

The accounting policies for the Parent Company are unchanged compared to last financial year and are the same as for the Group with the following additions. For a description of the accounting policies of the Group, please see note 1 – summary of significant accounting policies, page 50 – 56.

Supplementary accounting policies for the Parent company

Financial assets

In the financial statements of the Parent company, investments in subsidiaries are recorded under the equity method, which is at the respective share of the net asset values in subsidiaries. Any cost in excess of net assets in the acquired company is capitalised in the Parent company under Financial assets as part of investments in subsidiaries (Goodwill). Amortisation of goodwill is provided under the straight-line method over a period not exceeding 20 years, based on estimated useful life.

Net profit of subsidiaries less unrealised intercompany profits is recorded in the Income statement of the Parent company.

To the extent it exceeds declared dividends from such companies, net revaluation of investments in subsidiaries is transferred to net revaluation reserve according to the equity method under equity.

Fair value adjustments of financial assets categorised as Available for sale are recognised in the Parent company in the Income statement.

The profit in subsidiaries is shown as profit after tax.

Tax

The Parent company is assessed jointly for Danish tax purposes with its Danish Parent company Novo Nordisk A/S and other Danish affiliated companies. The Danish jointly taxed companies are included in a Danish on-account tax payment scheme for Danish corporate income tax. All current taxes under the scheme are recorded in the individual companies.

Cash flow statement

In conformity with section 86.4 of the Danish Financial Statements Act, no Cash Flow Statement is prepared for the Parent Company. Please refer to the Cash Flow Statement for the Group.

Notes – Parent Company
(DKK 1,000)

	2009	2008
Note 2 Sales		
Sales value of other sales	48,362	83,137
Sales value of completed contracts during the year	951,937	1,234,789
Sales value of work in progress, end of year	80,660	101,288
Sales value of work in progress, beginning of year	<u>(101,288)</u>	<u>(220,876)</u>
Total	<u>979,671</u>	<u>1,198,338</u>
Note 3 Employee costs		
Wages and salaries	523,303	548,304
Pensions	51,509	51,291
Share-based payment cost	4,811	18,687
Other contributions to social security	7,052	6,586
Other employee costs	<u>16,855</u>	<u>20,189</u>
Total	<u>603,530</u>	<u>645,057</u>
Included in the income statement under the following headings:		
Cost of sales	531,771	567,650
Sales and distribution costs	13,688	12,901
Administrative expenses	<u>58,071</u>	<u>64,506</u>
Total	<u>603,530</u>	<u>645,057</u>
The average number of full-time employees in 2009 was 835 compared to 889 in 2008. At the end of the year the company had 807 employees compared to 882 at year end 2008.		
For information on remuneration to the Board of Directors and Executive Management please refer to note 3 in the Consolidated notes.		
Note 4 Financial income		
Interest income from subsidiaries	2,316	2,365
Interest income bank	13	249
Dividend from shares	-	387
Currency exchange gains, capital gains and other financial income	<u>417</u>	<u>234</u>
Total	<u>2,746</u>	<u>3,235</u>
Dividend from Novo Nordisk A/S shares amounts to DKK 0k (387k in 2008).		
Note 5 Financial expenses		
Interest expenses to group companies	2,390	5,050
Currency exchange loss and other financial expenses	<u>8,629</u>	<u>2,600</u>
Total	<u>11,019</u>	<u>7,650</u>

Notes – Parent Company
(DKK 1,000)

Note 6 Intangible assets

2009

	ERP-system and software	Total
Cost at 1 January	39,474	39,474
Additions during the year	-	-
Cost at 31 December	<u>39,474</u>	<u>39,474</u>
Depreciation and impairment losses at 1 January	36,429	36,429
Depreciation for the year	1,345	1,345
Depreciation and impairment losses at 31 December	<u>37,774</u>	<u>37,774</u>
Carrying amount at 31 December	<u>1,700</u>	<u>1,700</u>

2008

	ERP-system and software	Total
Cost at 1 January	38,346	38,346
Additions during the year	1,128	1,128
Cost at 31 December	<u>39,474</u>	<u>39,474</u>
Depreciation and impairment losses at 1 January	30,124	30,124
Depreciation for the year	6,305	6,305
Depreciation and impairment losses at 31 December	<u>36,429</u>	<u>36,429</u>
Carrying amount at 31 December	<u>3,045</u>	<u>3,045</u>

Note 7 Property, plant and equipment

2009

	Leasehold improve- ments	Other equipment	Total
Cost at 1 January	10,232	40,744	50,976
Additions during the year	-	1,412	1,412
Disposals during the year	-	(7,878)	(7,878)
Cost at 31 December	<u>10,232</u>	<u>34,278</u>	<u>44,510</u>
Depreciation and impairment losses at 1 January	2,472	31,817	34,289
Depreciation for the year	1,023	5,658	6,681
Disposals during the year	-	(6,199)	(6,199)
Depreciation and impairment losses at 31 December	<u>3,495</u>	<u>31,276</u>	<u>34,771</u>
Carrying amount at 31 December	<u>6,737</u>	<u>3,002</u>	<u>9,739</u>

2008

	Leasehold improve- ments	Other equipment	Total
Cost at 1 January	10,232	39,908	50,140
Additions during the year	-	2,052	2,052
Disposals during the year	-	(1,216)	(1,216)
Cost at 31 December	<u>10,232</u>	<u>40,744</u>	<u>50,976</u>
Depreciation and impairment losses at 1 January	1,449	25,208	26,657
Depreciation for the year	1,023	6,609	7,632
Disposals during the year	-	-	-
Depreciation and impairment losses at 31 December	<u>2,472</u>	<u>31,817</u>	<u>34,289</u>
Carrying amount at 31 December	<u>7,760</u>	<u>8,927</u>	<u>16,687</u>

Notes – Parent Company
(DKK 1,000)

Note 8 Investments in subsidiaries and joint ventures

Investments in subsidiaries

	2009	2008
Cost at 1 January	141,685	149,821
Additions during the year	121,372	6,918
Adjustment previous year	11,045	(13,848)
Disposals during the year	-	(1,206)
Cost at 31 December	<u>274,102</u>	<u>141,685</u>
Revaluation at 1 January	(88,768)	(27,921)
Exchange rate adjustments	(898)	(3,298)
Net profit/(loss) for the year	(7,646)	(57,549)
Revaluation on disposals during the year	-	-
Revaluation at 31 December	<u>(97,312)</u>	<u>(88,768)</u>
Depreciation and impairment losses at 1 January	(31,988)	(19,093)
Exchange rate adjustments	273	877
Amortisation of goodwill	(11,220)	(13,772)
Depreciation on disposals during the year	-	-
Impairment losses and depreciation at 31 December	<u>(42,935)</u>	<u>(31,988)</u>
Carrying amount at 31 December	<u>133,855</u>	<u>20,929</u>

Aggregated financial information of subsidiaries:

Company	Domicile	Share of ownership	Share capital	Net Equity	Profit/Loss
NNE Pharmaplan France SAS	Chatres, France	100%	EUR 37k	9,732	(1,269)
NNE Pharmaplan US Inc.	Clayton, USA	100%	USD 375k	2,473	(5,418)
NNET Pharmaplan (Tianjin) Co. Ltd.	Tianjiin, China	100%	USD 450k	50,221	24,170
NNE Pharmaplan Sweden AB	Stockholm, Sweden	100%	SEK 100k	3,551	(3,943)
NNE Pharmaplan GmbH	Bad Homburg, Germany	100%	EUR 550k	12,701	(21,081)
NNE Pharmaplan Ltd.	Dublin, Ireland	100%	EUR 1	472	(105)
				79,150	(7,646)
Goodwill, etc. at 31 December				54,705	
Amortisation of goodwill, etc.					(11,220)
				<u>133,855</u>	<u>(18,866)</u>

Aggregated financial information of joint ventures

Ownership in associated companies:

Company	Domicile	Share of ownership
Geanne I/S (Joint venture)	Skanderborg, Denmark	50%

Investments in Geanne I/S are consolidated by the pro rata method.

For further information please refer to note 11 in the Consolidated notes.

Notes – Parent Company
(DKK 1,000)

Note 9 Work in progress and payments on account for work in progress

	2009	2008
Current account contracts		
Work in progress	(1,271)	41,740
Prepayments on account	-	-
Total	(1,271)	41,740
Fixed price contracts		
Work in progress	81,931	59,548
Prepayments on account	(82,091)	(60,612)
Total	(160)	(1,064)
Total	(1,431)	40,676

This is classified in the balance as shown below:

	Current Account	Fixed Price	Total	Total
Current assets	(1,271)	3,806	2,535	48,212
Current liabilities	-	(3,966)	(3,966)	(7,536)
	(1,271)	(160)	(1,431)	40,676

Work in progress, includes an unrealised profit of DKK 19.9 million at 31 December 2009 against an unrealised profit of DKK 18.1 million at 31 December 2008.

Note 10 Share capital

Share capital at the end of the year:

A share capital (167 shares of DKK 1,000)	167	167
B share capital (333 shares of DKK 1,000)	333	333
Total share capital	500	500

The share capital in NNE Pharmaplan A/S is divided into A shares and B shares. The A shares have 10 votes per DKK 500 of the A share capital, whereas the B shares have one vote per DKK 500 of the B share capital. There are no transferability restrictions on the B shares, while the owners of the A shares has a right of first refusal in case of any transfer of A shares.

Note 11 Other liabilities

Holiday allowance payable and staff related items	110,201	108,120
Accrued expenses	629	17
Financial lease commitments	1,967	3,235
VAT, taxes and other contributions to social security	42,633	35,871
Total	155,430	147,243
Current liabilities	155,430	147,243
Non-current liabilities	-	-
Total	155,430	147,243

Notes – Parent Company
(DKK 1,000)

Note 12 Commitments

Operating leases

The operating lease commitments are related to non-cancellable operating leases, related to office rent, company cars and copying machines. Expenses related to lease rentals amount to DKK 31.5 millioner in 2009 and DKK 30.5 millioner in 2008.

Other Commitments

The internal consultants have a notice period of 3 months or less.

Operating leases and other commitments is payable within the following periods as from the balance sheet date:

Within one year	31,711	32,996
Between one and two years	26,601	27,275
Between two and three years	24,873	25,040
Between three and four years	24,731	24,443
Between four and five years	24,577	23,868
After five years	40,666	61,705
Total	173,159	195,327

Guarantees

Guarantee for lease commitments	12,141	11,445
Bank guarantees	40,928	40,978
Guarantees given to customers	7,351	4,371
Total	60,420	56,794

Guarantees given through joint ventures

-	3,333
---	--------------

Other

NNE Pharmaplan A/S has a joint liability for 2004 and previous years with Novo Nordisk A/S and the other jointly taxed companies for the tax payable under the joint taxation programme.

Note 13 Fees to statutory auditors

Statutory audit fee to PricewaterhouseCoopers	665	510
Audit-related services	151	662
Tax advisory services	22	320
Other services	-	50
Total	838	1,542

Note 14 Transactions with related parties

For information regarding transactions with related parties please refer to note 24 in the Consolidated notes.